Skip to main content

Table 2 Basic characteristics

From: Efficacy and safety of basal-bolus insulin at 1:1.5 ratio compared to 1:1 ratio using a weight-based initiation and titration (WIT2) algorithm in hospitalized patients with type 2 Diabetes: a multicenter, randomized, clinical study

 

1:1.5

1:1

n=89

n=93

Demographic characteristics

   Sex (M, %)

57 (64.0)

53 (57.0)

  Age (years)

57.2 ± 12.8

57.3 ± 10.1

  History of diabetes (years)

4.4±5.8

5.8 ±6.9

  Weight (kg)

66.8±11.4

65.4±10.8

  BMI (kg/m2)

25.0±3.3

24.2 ±3.8

Clinical characteristics

  HbA1c(%)

11.7±2.1

12.1±1.9

  Admission BG (mmol/L) 

19.1±5.5

18.2 ±5.3

  Diagnosis on admission (%)

   Isolated hyperglycemia

62 (69.7)

64 (68.8)

   DK/DKA

15 (16.9)

19 (20.4)

  Infection

12 (13.4)

10 (10.8)

 Therapy before admission

   None

49 (55.1)

44 (47.3)

   OAD

25 (28.1)

29 (31.2)

   Insulin

2 (2.2)

2 (2.1)

   OAD + insulin

13 (14.6)

18 (19.4)

  1. Values are n (%) or mean ± SD unless otherwise stated. *, median (range). BG, blood glucose. BMI body mass index, DKA diabetic ketoacidosis. Infection sites include urinary tract, lung, skin, and perianal area. AGI alpha-glucosidase inhibitor, TZD thiazolidinediones, DPP4i, dipeptidyl peptidase 4 inhibitor, SGLT2i sodium–glucose co-transporter 2 inhibitor. Sulphonylurea includes gliclazide, glimepiride and glipizide